NCT00403507

Brief Summary

The purpose of the study is to determine if participation in an exercise program helps memory loss from getting worse, and if it improves daily functioning and attitudes of those with probable Alzheimer's disease. It will involve participation of both the person with memory loss and someone who knows their daily activities (e.g., husband, wife, adult child, or caregiver).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
79

participants targeted

Target at P25-P50 for phase_2 alzheimer-disease

Timeline
Completed

Started Oct 2006

Typical duration for phase_2 alzheimer-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2006

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

November 21, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 23, 2006

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2009

Completed
Last Updated

May 11, 2011

Status Verified

November 1, 2006

Enrollment Period

3 years

First QC Date

November 21, 2006

Last Update Submit

May 9, 2011

Conditions

Keywords

Mild DementiaMild AlzheimerCognitive ImpairmentCholinesterase InhibitorExercisePhysical activityBehaviorMemory loss

Outcome Measures

Primary Outcomes (4)

  • For the intervention group: Change in cognitive performance relative to baseline

    baseline & 20 week follow-up

  • Group differences in cognitive performance following intervention and relative to wait-list control group

    baseline & 20 week follow-up

  • For the intervention group: Change in attitudes, including self-report of well-being and cognitive abilities relative to baseline

    baseline & 20 week follow-up

  • Group differences in attitudes, including self-report of well-being, following intervention and relative to wait-list control group

    baseline & 20 week follow-up

Secondary Outcomes (2)

  • For the intervention group: Change in knowledgeable informant's ratings of function, behavior, and attitudes

    baseline & 20 week follow-up

  • Group differences in knowledgeable informant's ratings of function, behavior, and attitudes following intervention and relative to wait-list control group

    baseline & 20 week follow-up

Study Arms (4)

Clean Control

NO INTERVENTION

Probable Alzheimer's disease in the context of no excluding medical conditions.

Behavioral: Participation in a monitored exercise program

CoMorbid Control

NO INTERVENTION

Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.

Behavioral: Participation in a monitored exercise program

Clean Exercise

EXPERIMENTAL

Probable Alzheimer's disease in the context no comorbid medical conditions.

Behavioral: Personalized aerobic and strength training.

CoMorbid Exercise

EXPERIMENTAL

Probable Alzheimer's disease in the context of well-controlled comorbid medical conditions.

Behavioral: Personalized aerobic and strength training.

Interventions

No contact with control group during 20 weeks.

Clean ControlCoMorbid Control

Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.

Clean ExerciseCoMorbid Exercise

Eligibility Criteria

Age65 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)

You may qualify if:

  • Age is 65 through 89 years old.
  • Completed more than an 8th grade education.
  • Native English speaker.
  • Diagnosis of probable Alzheimer's disease by a primary care physician or specialty clinic.
  • Taking a cholinesterase inhibitor at a therapeutic dose for at least two weeks prior to admission to study (following minimum titration of four weeks), but no other prescribed medication for cognitive functioning (e.g., memantine/Namenda).
  • May have one unstable physical illness that is being treated or a few controlled physical illnesses, is on few medications, and appears no more than mildly ill.
  • Treated stable hypertension \& hyperlipidemia are permissible, but resting blood pressure must be \<170/100 mm Hg.
  • Normal TSH \& Vitamin B12 levels, as confirmed by laboratory data within 3 years.
  • Able to participate a three-day/week physical activity program (No orthopedic, neurologic, or behavioral limitations that may preclude exercise training) for up to 6 months.
  • Patient has a knowledgeable informant who can report the day-to-day activities of participant (e.g., spouse, adult child, paid caregiver).
  • Able to give assent/consent to research study.

You may not qualify if:

  • History of learning or developmental disability.
  • Treatment with hormone replacement therapy during the last year.
  • History of psychiatric condition (including depression).
  • Evidence of serious cardiac condition or significant small vessel disease (e.g., heart bypass surgery, angina, arrhythmia, dyspnea, insulin-dependent diabetes with neuropathy, confluent white matter alterations on structural MRI or CT scan).
  • History of neurologic condition (e.g., large vessel stroke, seizures, Parkinsonism).
  • History of heavy metals exposure.
  • History of sleep disturbance (e.g., treated apnea, insomnia).
  • History of brain injury (including concussion of \>10 minutes).
  • History of delirium (change in mental status due to medications) for the past year.
  • No pharmaceutical treatment for mood currently, or history of longstanding depression.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

LDS Hospital

Salt Lake City, Utah, 84143, United States

Location

MeSH Terms

Conditions

Alzheimer DiseaseMemory DisordersDementiaCognitive DysfunctionMotor ActivityBehavior

Interventions

Resistance Training

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersNeurobehavioral ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsCognition Disorders

Intervention Hierarchy (Ancestors)

Exercise TherapyRehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy ModalitiesPhysical Conditioning, HumanExerciseMotor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Kelly Garrett, Ph.D.

    Intermountain Health Care- LDS Hosptial

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 21, 2006

First Posted

November 23, 2006

Study Start

October 1, 2006

Primary Completion

October 1, 2009

Study Completion

October 1, 2009

Last Updated

May 11, 2011

Record last verified: 2006-11

Locations